Role and Mechanism of miR-1269a on Targeted Regulation of HOXD10 in Invasion of Cholangiocarcinoma Cells

YANG Haixia; MI Jianqiang; LIANG Jun; SHAO Qiuju; QI Yuhong; WANG Qiming; CHANG Hao; LI Enxiao

doi:10.3971/j.issn.1000-8578.2018.18.0175

Cancer Research on Prevention and Treatment > 2018 > 45(11): 894-899. > DOI: 10.3971/j.issn.1000-8578.2018.18.0175

YANG Haixia, MI Jianqiang, LIANG Jun, SHAO Qiuju, QI Yuhong, WANG Qiming, CHANG Hao, LI Enxiao. Role and Mechanism of miR-1269a on Targeted Regulation of HOXD10 in Invasion of Cholangiocarcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 894-899. DOI: 10.3971/j.issn.1000-8578.2018.18.0175

Citation:

PDF (5459 KB)

Role and Mechanism of miR-1269a on Targeted Regulation of HOXD10 in Invasion of Cholangiocarcinoma Cells

YANG Haixia^{1, 2},
MI Jianqiang³,
LIANG Jun^{1, 2},
SHAO Qiuju^{1, 2},
QI Yuhong^{1, 2},
WANG Qiming^{1, 2},
CHANG Hao^{1, 2},
LI Enxiao⁴

1.
Department of Radiotherapy, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China
2.
Cancer Institute of Fourth Military Medical University, Xi'an 710038, China
3.
Department of Pathology, First Affiliated Hospital of He'nan Science and Technology University, Luoyang 471003, China
4.
Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710062, China

More Information

Received Date: February 04, 2018
Revised Date: August 26, 2018
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To explore the possible mechanism of microRNA-1269a(miR-1269a) on the targeted regulation of HOXD10 in the invasion of human cholangiocarcinoma (CCC) cells.
Methods
We detected six miRNAs levels in human CCC samples and cells for screening miR-1269a as the research object.miR-1269a mimic and inhibitor were transfected into four CCC cells by Lipofectamine liposome respectively.The expressions of HOXD10 mRNA and protein were detected by real-time quantitative PCR (qPCR) and Western blot.The effect of miR-1269a on the invasion of CCC cells was observed.Double luciferase reporter assay was applied to verify the targeting relationship between miR-1269a and HOXD10.
Results
miR-1269a expression was significantly upregulated in CCC tissues, compared with adjacent normal tissues (P=0.0023).The mRNA and protein levels of HOXD10 in miR-1269a mimic transfection group were lower than those in control group (Mz-CHA-1:P=0.0025;RBE:P=0.0038).miR-1269a mimic significantly elevated the invasion capacity of CCC cells (Mz-CHA-1:P=0.004;RBE:P=0.004), while miR-1269a inhibitor remarkably inhibited the invasion (QBC939:P=0.16;HCCC9810:P=0.13).Double luciferase reporter gene test showed that miR-1269a could significantly inhibit the luciferase activity of wild-type HOXD10-3'UTR, but had no effect on the luciferase activity of mutant plasmid transfected cells.
Conclusion
miR-1269a may regulate the invasion of CCC cells by targeting HOXD10, and could be used as an effective target for the molecular therapy of CCC.
- Cholangiocarcinoma(CCC),
- miR-1269a,
- HOXD10(HomeoboxD10),
- Invasion

FullText(HTML)

References (19)

References

[1]	Cheung AC, Lorenzo Pisarello MJ, LaRusso NF.Pathobiology of biliary epithelia[J].Biochim Biophys Acta, 2018, 1864(4 Pt B):1220-31. doi: 10.1016-S0016-5085(97)70244-0/
[2]	Razumilava N, Gores GJ.Cholangiocarcinoma[J].Lancet, 2014, 383(9935):2168-79. doi: 10.1016/S0140-6736(13)61903-0
[3]	Yang H, Zhou J, Mi J, et al.HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma[J].Oncol Rep, 2015, 34(4):1681-91. doi: 10.3892/or.2015.4194
[4]	Ou Y, Zhang Q, Tang Y, et al.DNA methylation enzyme inhibitor RG108 suppresses the radioresistance of esophageal cancer[J].Oncol Rep, 2018, 39(3):993-1002. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=84d31284a5e6c44ea1daf388ace92f53
[5]	Zhang Y, Yang P, Sun T, et al.miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis[J].Nat Cell Biol, 2013, 15(3):284-94. doi: 10.1038/ncb2690
[6]	Olaizola P, Lee-Law PY, Arbelaiz A, et al.MicroRNAs and extracellular vesicles in cholangiopathies[J].Biochim Biophys Acta, 2018, 1864(4 Pt B):1293-307. https://linkinghub.elsevier.com/retrieve/pii/S0925443917302247
[7]	Ma L, Teruya-Feldstein J, Weinberg RA.Tumour invasion and metastasis initiated by microRNA-10b in breast cancer[J].Nature, 2007, 449(7163):682-8. doi: 10.1038/nature06174
[8]	Li Q, Ding C, Chen C, et al.miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2014, 29(4):835-42. doi: 10.1111/jgh.2014.29.issue-4
[9]	Bu P, Wang L, Chen KY, et al.miR-1269 promotes metastasis and forms a positive feedback loop with TGF-beta[J].Nat Commun, 2015, 6:6879. doi: 10.1038/ncomms7879
[10]	Hu X, Chen D, Cui Y, et al.Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10[J].Sci Rep, 2013, 3:3423. doi: 10.1038/srep03423
[11]	Yang H, Liang J, Zhou J, et al.Knockdown of RHOC by shRNA suppresses invasion and migration of cholangiocellular carcinoma cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal transition[J].Mol Med Rep, 2016, 13(6):5255-61. doi: 10.3892/mmr.2016.5170
[12]	Yang H, Lu X, Liu Z, et al.FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells[J].Oncotarget, 2015, 6(8):6310-25. http://pubmedcentralcanada.ca/pmcc/articles/PMC4467439/
[13]	Huang M, Su L, Yang L, et al.Effect of exogenous TGF-beta1 on the cadmium-induced nephrotoxicity by inhibiting apoptosis of proximal tubular cells through PI3K-AKT-mTOR signaling pathway[J].Chem Biol Interact, 2017, 269:25-32. doi: 10.1016/j.cbi.2017.03.010
[14]	Ko DY, Shin JM, Um JY, et al.Rapamycin inhibits transforming growth factor beta 1 induced myofibroblast differentiation via the phosphorylated-phosphatidylinositol 3-kinase mammalian target of rapamycin signal pathways in nasal polyp-derived fibroblasts[J].Am J Rhinol Allergy, 2016, 30(6):211-7. doi: 10.2500/ajra.2016.30.4389
[15]	Luo D, Hu S, Tang C, et al.Mesenchymal stem cells promote cell invasion and migration and autophagy-induced epithelial-mesenchymal transition in A549 lung adenocarcinoma cells[J].Cell Biochem Funct, 2018, 36(2):88-94. doi: 10.1002/cbf.v36.2
[16]	Zhong W, Tong Y, Li Y, et al.Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma via activating Akt/NF-κB signaling by paracrine CCL5[J].Oncotarget, 2017, 8(43):73693-704 http://pubmedcentralcanada.ca/pmcc/articles/PMC5650292/
[17]	Patman G.Liver cancer:TGF-β and cholangiocarcinoma[J].Nat Rev Gastroenterol Hepatol, 2016, 13(1):2-3. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0225747915/
[18]	Wang H, Li C, Jian Z, et al.TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4[J].PLoS One, 2015, 10(10):e0136703. doi: 10.1371/journal.pone.0136703
[19]	Chen Y, Ma L, He Q, et al.TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma[J].Biol Res, 2015, 48:26. doi: 10.1186/s40659-015-0016-9

[1]	SHAN Baoen. Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 833-841. DOI: 10.3971/j.issn.1000-8578.2023.22.1423
[2]	QIAO Shishi, KONG Tiandong, YU Dan, YANG Zhen, PAN Yanfeng, ZHAO Lingdi. A Real-world Study of Anti-PD-1 Antibody Combination Therapy in Advanced Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 293-297. DOI: 10.3971/j.issn.1000-8578.2023.22.0852
[3]	YAN Guangning, YU Ling, LAI Xuwen, YE Danli, WANG Wei, WANG Zhuocai. Correlation Between PD-1/CTLA-4 Expressions with C linicopathological Features and Prognosis of Osteosarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 63-68. DOI: 10.3971/j.issn.1000-8578.2023.22.0483
[4]	QI Lin, ZHANG Zhao, WANG Suyun, LIU Guimin, WANG Rui, FU Jianzhu, CHENG Zhiyong. Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1021-1027. DOI: 10.3971/j.issn.1000-8578.2022.22.0188
[5]	CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
[6]	LAI Yanliang, GENG Yan, YANG Bingquan. Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1035-1040. DOI: 10.3971/j.issn.1000-8578.2021.21.0365
[7]	YU Lin, LI Guangping, ZHOU Changyu, FU Huaying. Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 794-798. DOI: 10.3971/j.issn.1000-8578.2021.20.1449
[8]	MA Yinjuan, YANG Xiaying, WANG Ying, WANG Xuan, PAN Yaozhu. Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 647-651. DOI: 10.3971/j.issn.1000-8578.2021.21.0108
[9]	WANG Yufeng, YAO Nan, WANG Jun, MIN Guangtao. Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 346-352. DOI: 10.3971/j.issn.1000-8578.2020.19.0950
[10]	ZOU Hanhui, Li Tao. Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 141-146. DOI: 10.3971/j.issn.1000-8578.2020.19.0945

Cited By

Cited by

Periodical cited type(12)

1.	梅琪，袁牧，钱景瑜，刘若宇，谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察. 蚌埠医学院学报. 2024(01): 51-54+58 .
2.	李丽敏，王璐，曹阳博，刘栋利，陈鹏飞. 肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析. 癌症进展. 2024(01): 72-75 .
3.	费睿成，亓民. PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果. 实用中西医结合临床. 2024(10): 16-19 .
4.	刘小梅，钟梅，刘浩，易军，王洪云. 晚期肝癌免疫相关治疗的获益和不良反应临床研究. 基层医学论坛. 2023(19): 20-22+35 .
5.	何晓锐，王淑红. 阿替利珠单抗联合贝伐珠单抗治疗晚期肝癌的临床效果. 临床医学研究与实践. 2023(27): 29-32 .
6.	陈方红，刘娱，边界. PD-1抑制剂治疗肝癌患者的临床疗效及ECOG-PS评分联合Child-Pugh分级对肿瘤超进展的预测价值. 广西医学. 2023(15): 1800-1806 .
7.	郭稳稳，程昌盛，吴燕，林文东，赖辉强，黄吉荣，龙高云. 安罗替尼治疗晚期肝癌的疗效及预后的影响因素. 临床与病理杂志. 2022(08): 1822-1828 .
8.	殷云飞，鲁邱阳. 抗PD-1单抗对中晚期肝癌患者近期疗效、外周血T淋巴细胞亚群指标的影响. 中国医学创新. 2021(13): 19-22 .
9.	李冰妍，陈林会，郑颖娟，梁天嵩，杨道科. 程序性死亡受体1抑制剂治疗远处转移鼻咽癌疗效观察. 肿瘤基础与临床. 2021(03): 207-211 .
10.	朱风婷，曾江正，姜靖雯，陈学武，张慧. 卡瑞利珠单抗联合射频消融术及FOLFOX方案治疗原发性肝癌疗效研究. 中国药业. 2021(15): 38-41 .
11.	王俊旗，徐锋. 程序性死亡受体1及其配体PD-L1、细胞毒性T淋巴细胞相关抗原4抑制剂在晚期肝癌治疗中的进展. 中华普通外科学文献(电子版). 2021(04): 304-308 .
12.	鄢清元，熊巍，杨文平. 晚期肝癌患者索拉非尼分子靶向治疗的有效性及对疾病控制率的影响研究. 中国医学创新. 2021(29): 173-177 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1376) PDF downloads (301) Cited by(12)

Turn off MathJax

Article Contents

Abstract

References

Role and Mechanism of miR-1269a on Targeted Regulation of HOXD10 in Invasion of Cholangiocarcinoma Cells